In recent months, Catalyst Pharmaceuticals secured U.S. patent protections extending Firdapse’s exclusivity to 2035, resolved key patent disputes, expanded Firdapse’s label to pediatric LEMS patients, ...

Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...

Catalyst Pharmaceuticals, Inc. CPRX announced positive top-line results from a second phase III study of Firdapse. As the lead pipeline candidate of the company, Firdapse is being developed for the ...

What Tools Were Used in the Studies for Lambert-Eaton Myasthenic Syndrome (LEMS)? Before describing how Firdapse was studied, it is important to understand the tools that were used in the studies.

Shares of Catalyst Pharmaceuticals, Inc. CPRX have rallied 25.3% in the past three months compared with the industry’s rise of 2.5%. Zacks Investment Research Image Source: Zacks Investment Research ...

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation ...

We issued an updated research report on Catalyst Pharmaceuticals Inc. CPRX on Sep 7, 2020. Catalyst’s share price has declined 17.9% compared with the industry’s decline of 9% in the year so far. The ...

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and ...

Catalyst Pharmaceuticals, Inc.’s CPRX lead drug, Firdapse (amifampridine), is approved in the United States and Europe for the treatment of adult patients with Lambert-Eaton myasthenic syndrome (“LEMS ...

Management reaffirmed full year 2025 revenue guidance of $545 million to $565 million. Product-specific guidance includes $355 million to $360 million for FIRDAPSE, $100 million to $110 million for ...